310 related articles for article (PubMed ID: 8039604)
1. Identification of glutamic acid decarboxylase autoantibody heterogeneity and epitope regions in type I diabetes.
Ujihara N; Daw K; Gianani R; Boel E; Yu L; Powers AC
Diabetes; 1994 Aug; 43(8):968-75. PubMed ID: 8039604
[TBL] [Abstract][Full Text] [Related]
2. Murine monoclonal glutamic acid decarboxylase (GAD)65 antibodies recognize autoimmune-associated GAD epitope regions targeted in patients with type 1 diabetes mellitus and stiff-man syndrome.
Ziegler B; Schlosser M; Lühder F; Strebelow M; Augstein P; Northemann W; Powers AC; Ziegler M
Acta Diabetol; 1996 Sep; 33(3):225-31. PubMed ID: 8904930
[TBL] [Abstract][Full Text] [Related]
3. Autoantigenic reactivity of diabetes sera with a hybrid glutamic acid decarboxylase GAD67-65 molecule GAD67(1-101)/GAD65(96-585).
Teoh KL; Fida S; Rowley MJ; Mackay IR
Autoimmunity; 1998; 28(4):259-66. PubMed ID: 9892508
[TBL] [Abstract][Full Text] [Related]
4. Human B cells secreting immunoglobulin G to glutamic acid decarboxylase-65 from a nondiabetic patient with multiple autoantibodies and Graves' disease: a comparison with those present in type 1 diabetes.
Tremble J; Morgenthaler NG; Vlug A; Powers AC; Christie MR; Scherbaum WA; Banga JP
J Clin Endocrinol Metab; 1997 Aug; 82(8):2664-70. PubMed ID: 9253351
[TBL] [Abstract][Full Text] [Related]
5. Autoreactive epitopes defined by diabetes-associated human monoclonal antibodies are localized in the middle and C-terminal domains of the smaller form of glutamate decarboxylase.
Richter W; Shi Y; Baekkeskov S
Proc Natl Acad Sci U S A; 1993 Apr; 90(7):2832-6. PubMed ID: 7681990
[TBL] [Abstract][Full Text] [Related]
6. Glutamic acid decarboxylase-67 (GAD67): expression relative to GAD65 in human islets and mapping of autoantibody epitopes.
Cram DS; Faulkner-Jones B; Kun J; Harrison LC
Endocrinology; 1995 Mar; 136(3):1111-9. PubMed ID: 7532577
[TBL] [Abstract][Full Text] [Related]
7. Detection of GAD65 antibodies in diabetes and other autoimmune diseases using a simple radioligand assay.
Petersen JS; Hejnaes KR; Moody A; Karlsen AE; Marshall MO; Høier-Madsen M; Boel E; Michelsen BK; Dyrberg T
Diabetes; 1994 Mar; 43(3):459-67. PubMed ID: 8314020
[TBL] [Abstract][Full Text] [Related]
8. Autoantibodies in IDDM primarily recognize the 65,000-M(r) rather than the 67,000-M(r) isoform of glutamic acid decarboxylase.
Hagopian WA; Michelsen B; Karlsen AE; Larsen F; Moody A; Grubin CE; Rowe R; Petersen J; McEvoy R; Lernmark A
Diabetes; 1993 Apr; 42(4):631-6. PubMed ID: 8454115
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of autoantibodies to the 65- and 67-kD isoforms of glutamate decarboxylase in insulin-dependent diabetes mellitus.
Seissler J; Amann J; Mauch L; Haubruck H; Wolfahrt S; Bieg S; Richter W; Holl R; Heinze E; Northemann W
J Clin Invest; 1993 Sep; 92(3):1394-9. PubMed ID: 8376591
[TBL] [Abstract][Full Text] [Related]
10. Identification of protein tyrosine phosphatase-like IA2 (islet cell antigen 512) as the insulin-dependent diabetes-related 37/40K autoantigen and a target of islet-cell antibodies.
Bonifacio E; Lampasona V; Genovese S; Ferrari M; Bosi E
J Immunol; 1995 Dec; 155(11):5419-26. PubMed ID: 7594559
[TBL] [Abstract][Full Text] [Related]
11. Recognition of glutamic acid decarboxylase (GAD) by autoantibodies from different GAD antibody-positive phenotypes.
Hampe CS; Hammerle LP; Bekris L; Ortqvist E; Kockum I; Rolandsson O; Landin-Olsson M; Törn C; Persson B; Lernmark A
J Clin Endocrinol Metab; 2000 Dec; 85(12):4671-9. PubMed ID: 11134126
[TBL] [Abstract][Full Text] [Related]
12. Autoantibodies against glutamic acid decarboxylase 65 in Japanese patients with insulin-dependent diabetes mellitus (IDDM).
Yano M; Moriuchi R; Kawasaki E; Watanabe M; Saito K; Takino H; Akazawa S; Miyamoto T; Nagataki S
J Autoimmun; 1995 Feb; 8(1):83-96. PubMed ID: 7734039
[TBL] [Abstract][Full Text] [Related]
13. Autoantibodies against GAD65 rather than GAD67 precede the onset of type 1 diabetes.
Lühder F; Schlosser M; Mauch L; Haubruck H; Rjasanowski I; Michaelis D; Kohnert KD; Ziegler M
Autoimmunity; 1994; 19(2):71-80. PubMed ID: 7772705
[TBL] [Abstract][Full Text] [Related]
14. Cytoplasmic islet cell antibodies recognize distinct islet antigens in IDDM but not in stiff man syndrome.
Richter W; Seissler J; Northemann W; Wolfahrt S; Meinck HM; Scherbaum WA
Diabetes; 1993 Nov; 42(11):1642-8. PubMed ID: 8405707
[TBL] [Abstract][Full Text] [Related]
15. GAD autoantibodies in IDDM, stiff-man syndrome, and autoimmune polyendocrine syndrome type I recognize different epitopes.
Björk E; Velloso LA; Kämpe O; Karlsson FA
Diabetes; 1994 Jan; 43(1):161-5. PubMed ID: 7505244
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic islet cell cytoplasmic antibody in diabetes is represented by antibodies to islet cell antigen 512 and glutamic acid decarboxylase.
Myers MA; Rabin DU; Rowley MJ
Diabetes; 1995 Nov; 44(11):1290-5. PubMed ID: 7589826
[TBL] [Abstract][Full Text] [Related]
17. Two distinct glutamic acid decarboxylase auto-antibody specificities in IDDM target different epitopes.
Daw K; Powers AC
Diabetes; 1995 Feb; 44(2):216-20. PubMed ID: 7532143
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of GAD65 and GAD67 in human, rat, and mouse pancreatic islets.
Kim J; Richter W; Aanstoot HJ; Shi Y; Fu Q; Rajotte R; Warnock G; Baekkeskov S
Diabetes; 1993 Dec; 42(12):1799-808. PubMed ID: 8243826
[TBL] [Abstract][Full Text] [Related]
19. Radioimmunoassay for glutamic acid decarboxylase (GAD65) autoantibodies as a diagnostic aid for stiff-man syndrome and a correlate of susceptibility to type 1 diabetes mellitus.
Walikonis JE; Lennon VA
Mayo Clin Proc; 1998 Dec; 73(12):1161-6. PubMed ID: 9868413
[TBL] [Abstract][Full Text] [Related]
20. Combined analysis and single-step detection of GAD65 and IA2 autoantibodies in IDDM can replace the histochemical islet cell antibody test.
Wiest-Ladenburger U; Hartmann R; Hartmann U; Berling K; Böhm BO; Richter W
Diabetes; 1997 Apr; 46(4):565-71. PubMed ID: 9075795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
